Last reviewed · How we verify
NCT04589013: PRINCE
Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer
trial in Non-small Cell Lung Cancer in 106 participants. Completed in 29 September 2023.
29 September 2023
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 106 |
| Start date | 19 November 2020 |
| Primary completion | 29 September 2023 |
| Estimated completion | 29 September 2023 |
| Sites | 4 locations across France |
Conditions studied
- Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Sponsor
University Hospital, Lille
Who can join
18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study seeks to evaluate a multiparametric test including 6 immunohistochemical markers (PD-L1, CD8, FoxP3, PD1, CD163, CD15) to predict the cumulative incidence of death or progression on treatment with pembrolizumab+first line chemotherapy in metastatic non-small cell lung cancer, regardless of the PD-L1 status and in the absence of ALK, ROS1 or EGFR alteration.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer.
Pan Y, Fu Y, Zeng Y, Liu X, et al · · 2022 · cited 39× · PMID 35255999 · DOI 10.1186/s40364-022-00355-7 -
Prognostic and Therapeutic Role of CD15 and CD15s in Cancer.
Szlasa W, Wilk K, Knecht-Gurwin K, Gurwin A, et al · · 2022 · cited 15× · PMID 35565333 · DOI 10.3390/cancers14092203
Verify or expand the search:
- PubMed search for NCT04589013
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-small Cell Lung Cancer
Currently open trials in the same condition.
- NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
- NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
- NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
- NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
- NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04589013 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04589013.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing